Ticagrelor Removal by CytoSorb


Journal

PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780

Informations de publication

Date de publication:
Jun 2020
Historique:
pubmed: 18 10 2019
medline: 18 10 2019
entrez: 18 10 2019
Statut: ppublish

Résumé

Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes. CytoSorb The aim of this study was to evaluate the cost utility of intraoperative removal of ticagrelor using CytoSorb versus usual care among patients requiring emergent or urgent cardiac surgery in the UK. A de novo decision analytic model, based on current treatment pathways, was developed to estimate the short- and long-term costs and outcomes. Results from randomised clinical trials and national standard sources such as National Health Service (NHS) reference costs were used to inform the model. Costs were estimated from the NHS and Personal Social Services perspective. Deterministic and probabilistic sensitivity analyses (PSAs) explored the uncertainty surrounding the input parameters. In emergent cardiac surgery, intraoperative removal of ticagrelor using CytoSorb was less costly (£12,933 vs. £16,874) and more effective (0.06201vs. 0.06091 quality-adjusted life-years) than cardiac surgery without physiologic clearance of ticagrelor over a 30-day time horizon. For urgent cardiac surgery, the use of CytoSorb was less costly than any of the three comparators-delaying surgery for natural washout without adjunctive therapy, adjunctive therapy with short-acting antiplatelet agents, or adjunctive therapy with low-molecular-weight heparin. Results from the PSAs showed that CytoSorb has a high probability of being cost saving (99% in emergent cardiac surgery and 53-77% in urgent cardiac surgery, depending on the comparators). Cost savings derive from fewer transfusions of blood products and re-thoracotomies, and shorter stay in the hospital/intensive care unit. The implementation of CytoSorb as an intraoperative intervention for patients receiving ticagrelor undergoing emergent or urgent cardiac surgery is a cost-saving strategy, yielding improvement in perioperative and postoperative outcomes and decreased health resource use.

Sections du résumé

BACKGROUND BACKGROUND
Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes. CytoSorb
OBJECTIVE OBJECTIVE
The aim of this study was to evaluate the cost utility of intraoperative removal of ticagrelor using CytoSorb versus usual care among patients requiring emergent or urgent cardiac surgery in the UK.
METHODS METHODS
A de novo decision analytic model, based on current treatment pathways, was developed to estimate the short- and long-term costs and outcomes. Results from randomised clinical trials and national standard sources such as National Health Service (NHS) reference costs were used to inform the model. Costs were estimated from the NHS and Personal Social Services perspective. Deterministic and probabilistic sensitivity analyses (PSAs) explored the uncertainty surrounding the input parameters.
RESULTS RESULTS
In emergent cardiac surgery, intraoperative removal of ticagrelor using CytoSorb was less costly (£12,933 vs. £16,874) and more effective (0.06201vs. 0.06091 quality-adjusted life-years) than cardiac surgery without physiologic clearance of ticagrelor over a 30-day time horizon. For urgent cardiac surgery, the use of CytoSorb was less costly than any of the three comparators-delaying surgery for natural washout without adjunctive therapy, adjunctive therapy with short-acting antiplatelet agents, or adjunctive therapy with low-molecular-weight heparin. Results from the PSAs showed that CytoSorb has a high probability of being cost saving (99% in emergent cardiac surgery and 53-77% in urgent cardiac surgery, depending on the comparators). Cost savings derive from fewer transfusions of blood products and re-thoracotomies, and shorter stay in the hospital/intensive care unit.
CONCLUSIONS CONCLUSIONS
The implementation of CytoSorb as an intraoperative intervention for patients receiving ticagrelor undergoing emergent or urgent cardiac surgery is a cost-saving strategy, yielding improvement in perioperative and postoperative outcomes and decreased health resource use.

Identifiants

pubmed: 31620999
doi: 10.1007/s41669-019-00183-w
pii: 10.1007/s41669-019-00183-w
pmc: PMC7248150
doi:

Types de publication

Journal Article

Langues

eng

Pagination

307-319

Subventions

Organisme : Cytosorbents
ID : 01/08/2018

Références

JACC Basic Transl Sci. 2017 Apr 24;2(2):135-145
pubmed: 30167561
Asian Cardiovasc Thorac Ann. 2004 Mar;12(1):3-6
pubmed: 14977732
Braz J Cardiovasc Surg. 2018 Jan-Feb;33(1):59-63
pubmed: 29617503
BMC Health Serv Res. 2015 Jun 25;15:246
pubmed: 26108373
J Thromb Haemost. 2009 Sep;7(9):1556-65
pubmed: 19552634
BMJ Qual Improv Rep. 2014 Feb 21;2(2):
pubmed: 26734249
Ann Thorac Surg. 2019 Jul;108(1):45-51
pubmed: 30684482
Crit Care Med. 2006 Jun;34(6):1608-16
pubmed: 16607235
Health Qual Life Outcomes. 2018 Sep 20;16(1):191
pubmed: 30236119
J Am Coll Cardiol. 2011 Feb 8;57(6):672-84
pubmed: 21194870
J Thromb Haemost. 2016 Dec;14(12):2342-2352
pubmed: 27653814
Transfusion. 2018 Apr;58(4):846-853
pubmed: 29380872
Curr Cardiol Rev. 2009 May;5(2):125-32
pubmed: 20436853
J Hosp Infect. 2001 Mar;47(3):198-209
pubmed: 11247680
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Eur Heart J. 2014 Jun 14;35(23):1510-4
pubmed: 24748565
Blood. 2015 May 28;125(22):3484-90
pubmed: 25788700
BMJ Qual Improv Rep. 2017 Feb 10;6(1):
pubmed: 28243441
Circulation. 2003 Jun 17;107(23):2908-13
pubmed: 12796140
Med Arch. 2018 Feb;72(1):31-35
pubmed: 29416215
Circulation. 2007 Nov 27;116(22):2544-52
pubmed: 17998460
Ann Thorac Surg. 2012 Aug;94(2):460-7
pubmed: 22626751
N Engl J Med. 2019 May 9;380(19):1825-1833
pubmed: 30883047
Eur Heart J Qual Care Clin Outcomes. 2016 Jan 20;2(2):125-140
pubmed: 27042338
Ann Thorac Surg. 2019 Jun;107(6):1690-1698
pubmed: 30898561
Eur Heart J. 2016 Jan 7;37(2):189-97
pubmed: 26330426
Ther Clin Risk Manag. 2018 Jan 17;14:129-140
pubmed: 29398917

Auteurs

Mehdi Javanbakht (M)

Optimax Access UK Ltd, Market Access Consultancy, 20 Forth Banks Tower, Newcastle upon Tyne, NE1 3PN, UK. HEOR@deviceaccess.co.uk.
Device Access UK Ltd, Market Access Consultancy, University of Southampton Science Park, Chilworth Hampshire, UK. HEOR@deviceaccess.co.uk.

Miranda Trevor (M)

Newcastle University, Newcastle upon Tyne, UK.

Mohsen Rezaei Hemami (M)

PenTAG Health Technology Assessment, University of Exeter, Exeter, UK.

Kazem Rahimi (K)

The George Institute for Global Health, University of Oxford, Oxford, UK.

Michael Branagan-Harris (M)

Device Access UK Ltd, Market Access Consultancy, University of Southampton Science Park, Chilworth Hampshire, UK.

Fabian Degener (F)

CytoSorbents Europe GmbH, Berlin, Germany.

Daniel Adam (D)

CytoSorbents Europe GmbH, Berlin, Germany.

Franziska Preissing (F)

CytoSorbents Europe GmbH, Berlin, Germany.

Jörg Scheier (J)

CytoSorbents Europe GmbH, Berlin, Germany.

Suzanne F Cook (SF)

CERobs Consulting LLC, Chapel Hill, NC, USA.

Eric Mortensen (E)

CytoSorbents Corporation, Monmouth Junction, NJ, USA.

Classifications MeSH